HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joseph Meletiadis Selected Research

Fosfomycin

1/2022Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.
11/2021Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints.
1/2020Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model.
1/2020Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections.
1/2020Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome.
1/2020Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.
1/2020Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy.
1/2018Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.
12/2017Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joseph Meletiadis Research Topics

Disease

22Infections
01/2022 - 03/2007
14Aspergillosis
03/2021 - 02/2004
9Urinary Tract Infections (Urinary Tract Infection)
01/2022 - 10/2016
5Invasive Candidiasis
01/2021 - 01/2006
4Invasive Pulmonary Aspergillosis
12/2011 - 10/2006
3Candidiasis (Moniliasis)
01/2021 - 01/2006
3Mycoses (Diseases, Fungus)
12/2015 - 10/2006
3Invasive Fungal Infections
02/2009 - 05/2008
2Hematologic Neoplasms (Hematological Malignancy)
08/2022 - 03/2021
2Fungemia
08/2022 - 06/2016
2Candidemia
06/2022 - 01/2020
2COVID-19
06/2022 - 12/2020
2Keratitis
06/2021 - 04/2016
2Critical Illness (Critically Ill)
01/2021 - 12/2020
2Sepsis (Septicemia)
12/2020 - 01/2017
2Lung Injury
12/2020 - 06/2009
1Neoplasms (Cancer)
08/2022
1Shock
06/2022
1Diabetes Mellitus
11/2021
1Coinfection
09/2021
1Keratoconus
06/2021
1Pain (Aches)
06/2021
1Corneal Perforation
06/2021
1Respiratory Insufficiency (Respiratory Failure)
12/2020
1Osteomyelitis
11/2019
1Communicable Diseases (Infectious Diseases)
01/2019
1Bacterial Infections (Bacterial Infection)
01/2018
1Pneumonia (Pneumonitis)
01/2017
1Hodgkin Disease (Hodgkin's Disease)
10/2014
1Fever (Fevers)
10/2014
1Meningitis
10/2014
1Pulmonary Aspergillosis
06/2009
1Body Weight (Weight, Body)
06/2009
1Infarction (Infarctions)
06/2009
1Drug-Related Side Effects and Adverse Reactions
05/2008
1Cryptococcosis
09/2007
1Inflammation (Inflammations)
03/2007
1Neutropenia
03/2007

Drug/Important Bio-Agent (IBA)

9FosfomycinFDA Link
01/2022 - 12/2017
9Voriconazole (Vfend)FDA LinkGeneric
11/2016 - 02/2004
7Amphotericin B (Amphotericin)FDA LinkGeneric
07/2015 - 02/2004
6Anti-Bacterial Agents (Antibiotics)IBA
08/2022 - 06/2008
6EchinocandinsIBA
01/2021 - 05/2010
6AzolesIBA
01/2019 - 01/2013
6Antifungal AgentsIBA
02/2015 - 10/2006
5liposomal amphotericin BFDA Link
08/2022 - 10/2006
5Pharmaceutical PreparationsIBA
03/2021 - 02/2010
4AnidulafunginFDA Link
01/2021 - 06/2009
4Micafungin (FK463)FDA Link
12/2020 - 11/2014
4TriazolesIBA
11/2017 - 10/2006
3posaconazoleFDA Link
03/2021 - 02/2004
2Fluconazole (Zonal)FDA LinkGeneric
06/2022 - 01/2021
2galactomannanIBA
03/2021 - 06/2009
2DNA (Deoxyribonucleic Acid)IBA
03/2021 - 01/2006
2carbapenemaseIBA
01/2019 - 01/2017
2Nitrofurantoin (Macrodantin)FDA LinkGeneric
12/2017 - 10/2016
2isavuconazoleIBA
11/2017 - 11/2014
2Itraconazole (Sporanox)FDA LinkGeneric
04/2016 - 02/2004
1taniborbactamIBA
11/2021
1Meropenem (Merrem)FDA LinkGeneric
11/2021
1Cefepime (Maxipime)FDA LinkGeneric
11/2021
1A 17 (A-17)IBA
09/2021
1Dexamethasone (Maxidex)FDA LinkGeneric
06/2021
1Biomarkers (Surrogate Marker)IBA
03/2021
1TabletsIBA
01/2021
1siltuximabIBA
12/2020
1Monoclonal AntibodiesIBA
12/2020
1Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
12/2020
1tocilizumab (atlizumab)FDA Link
12/2020
1sarilumabIBA
12/2020
1Interleukin-6 (Interleukin 6)IBA
12/2020
1VancomycinFDA LinkGeneric
01/2020
1Tromethamine (Trometamol)FDA Link
01/2020
1MannansIBA
11/2019
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
11/2019
1Colistin (Coly-Mycin)FDA Link
01/2018
1PolyenesIBA
11/2017
1Tigecycline (Tygacil)FDA Link
01/2017
1Natamycin (Pimaricin)FDA Link
04/2016
1Caspofungin (Cancidas)FDA Link
12/2015
1Dihydrotachysterol (AT 10)IBA
06/2009
1FluoroquinolonesIBA
02/2009
1IgG Receptors (Fc gamma RI)IBA
09/2007
1ER 30346 (ravuconazole)IBA
10/2006
1Fungal DNAIBA
01/2006
1Terbinafine (Lamisil)FDA LinkGeneric
02/2004

Therapy/Procedure

17Therapeutics
01/2021 - 10/2006
2Length of Stay
08/2022 - 06/2022
2Catheters
08/2022 - 11/2021
1Penetrating Keratoplasty
06/2021
1Contact Lenses
06/2021
1Drug Therapy (Chemotherapy)
10/2014
1Salvage Therapy
10/2013
1Hematopoietic Stem Cell Transplantation
03/2007